NSB Stock Overview
Engages in the research and development of novel peptide-based pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeuroScientific Biopharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.037 |
| 52 Week High | AU$0.078 |
| 52 Week Low | AU$0.033 |
| Beta | 0.56 |
| 11 Month Change | -2.63% |
| 3 Month Change | -19.57% |
| 1 Year Change | -35.09% |
| 33 Year Change | -89.12% |
| 5 Year Change | -87.87% |
| Change since IPO | -83.56% |
Recent News & Updates
Recent updates
Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?
May 25
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Jan 27NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans
Oct 07Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth
Jun 23Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Mar 10We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely
Nov 18Shareholder Returns
| NSB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 2.8% | -3.6% | 1.5% |
| 1Y | -35.1% | 10.0% | 17.2% |
Return vs Industry: NSB underperformed the Australian Biotechs industry which returned 9.8% over the past year.
Return vs Market: NSB underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| NSB volatility | |
|---|---|
| NSB Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NSB has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NSB's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | n/a | www.neuroscientific.com |
NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer’s disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases.
NeuroScientific Biopharmaceuticals Limited Fundamentals Summary
| NSB fundamental statistics | |
|---|---|
| Market cap | AU$5.35m |
| Earnings (TTM) | AU$324.21k |
| Revenue (TTM) | AU$2.21m |
16.5x
P/E Ratio2.4x
P/S RatioIs NSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSB income statement (TTM) | |
|---|---|
| Revenue | AU$2.21m |
| Cost of Revenue | AU$24.29k |
| Gross Profit | AU$2.19m |
| Other Expenses | AU$1.86m |
| Earnings | AU$324.21k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0022 |
| Gross Margin | 98.90% |
| Net Profit Margin | 14.66% |
| Debt/Equity Ratio | 0% |
How did NSB perform over the long term?
See historical performance and comparison